Background. The goal of the present study was to characterize outcome and predictors of outcome of treatment interruption (TI) in highly active antiretroviral therapy (HAART)-treated patients.
survival in individuals with HIV infection. Despite these benefits, pill fatigue, adverse effects, and resistance continue to limit the effectiveness of HAART [1, 2] .
Treatment interruption (TI) has emerged as a possible means of ameliorating these problems. This strategy is most commonly used either in a cyclic approach based on predetermined time cycles (e.g., alternating 1 week of taking with 1 week of not taking the medications) [3] or in a program of cessation and reinitiation based on predetermined parameters (e.g., symptoms and thresholds for CD4 cell count and viral load). Theoretically, TI in either format may decrease the cumulative time a patient is exposed to antiretroviral therapy [4] , and thereby drug toxicity is reduced, the de- velopment of drug resistance is slowed, and costs to patients or the health care system are decreased [1] . The role of TI within the modern HAART strategy remains controversial [5] .
As a result of changes to treatment guidelines, many individuals who initiated HAART on the basis of the recommendations in place before 2000 might not do so today on the basis of the present guidelines. Beginning during early 2000, we systematically offered a strategy for TI to any HIV-positive adult who was without an AIDS-defining illness and had a nadir CD4 cell count 1200 cells/mm 3 . Patients who agreed to interrupt HAART were offered monthly monitoring, including measurement of CD4 cell count and plasma viral load. They were also encouraged to reinitiate HAART on the basis of present guidelines-namely, the development of an AIDS-defining illness or a CD4 cell count р200 cells/mm 3 . Syncytium-inducing (SI) HIV phenotypes are observed in ∼50% of untreated, HIV subtype B-infected patients with latestage disease. These phenotypes are associated with a rapid decline in CD4 cell count and limited survival time [6] . Most patients who are in the early stages of HIV disease have predominantly non-SI (NSI) HIV phenotypes. However, in ∼50% of patients, the virus changes from predominantly NSI phenotypes to predominantly SI phenotypes at some point. This change is associated with changes that occur in the HIV envelope sequence. We therefore hypothesized that the "11/25" genotype (the presence of basic residues at aa 11 and/or 25 of V3), which is associated with the SI phenotype [7] , would be associated with a faster time to reinitiation of HAART. The present analysis was conducted to evaluate factors associated with time to reinitiation of HAART after TI.
PATIENTS, MATERIALS, AND METHODS
HIV/AIDS treatment program. Medical services, antiretroviral drugs, plasma viral load measurements, and CD4 cell count monitoring are provided free of charge to eligible HIV-infected patients residing in British Columbia. The distribution of antiretroviral drugs is centralized through the provincial HIV/AIDS Drug Treatment Program, which is the only source of free antiretroviral drugs in the province, and it has been described in detail elsewhere [8, 9] .
The recommendations of the BC Centre for Excellence in HIV/AIDS's Advisory Committee on Drug Evaluation and Therapy have evolved in a fashion that is consistent with that of other Figure 1 . A, Kaplan-Meier product limit estimates of the probability of continuing treatment interruption (TI), stratified by nadir CD4 cell count (1250 or р250 cells/mm 3 ). B, Kaplan-Meier product limit estimates of the probability of continuing TI, stratified by genotype (11/25 genotype or no 11/25 genotype).
international treatment guidelines, such as those published by the International AIDS Society-USA [10] . Since 1999, the committee has recommended that antiretroviral therapy be initiated in asymptomatic patients with CD4 cell counts р200 cells/mm 3 .
Patients without an AIDS-defining illness who initiated antiretroviral therapy on the basis of previous guidelines and whose nadir CD4 cell counts were 1200 cells/mm 3 were advised of this change in the treatment guidelines and were offered the option of undergoing TI with monthly clinical monitoring, including measurement of CD4 cell count and plasma viral load.
Inclusion criteria.
A retrospective review of all charts in the tertiary care HIV outpatient clinic of the BC Centre for Excellence in HIV/AIDS and a database search of all patients in the HIV/AIDS Drug Treatment Program was conducted. Individuals who interrupted HAART between January 1999 and January 2003 were identified. Eligible patients were HIV-positive men and women у18 years old without an AIDS-defining illness and with a CD4 cell count 1200 cells/mm 3 at all times before the initiation of TI. All patients were advised to monitor CD4 cell count and plasma viral load at monthly intervals while not receiving HAART. Patients were also advised to reinitiate HAART if they developed any evidence of clinical disease progression (i.e., oral candidiasis or AIDS-defining illness) or, if while asymptomatic, they had a CD4 cell count р200 cells/ mm 3 or a CD4 cell fraction !14%. Data collection and statistical analysis. For each eligible patient, data that were collected included date of the initiation of TI, date of the reinitiation of HAART (if applicable), and CD4 cell count and plasma viral load before TI, during TI, and after the reinitiation of HAART (if applicable). The Amplicor Ultrasensitive assay (version 1.5; Roche) was used to measure plasma viral load, and it had quantitation limits of 50 and 100,000 (5.0 log 10 ) copies/mL. Plasma viral loads reported as !50 copies/mL were recorded as 45 (1.65 log 10 ) copies/mL, for nondetectable results, or 49 (1.69 log 10 ) copies/mL, for detectable results. Plasma viral loads 1100,000 were recorded as 100,010 copies/mL, for analytical purposes. CD4 cell counts were divided into multiple strata (200-250, 251-300, 301-350, and 1351 cells/mm 3 ), to investigate possible natural breaks in risk ratios (RRs).
V3 genotyping was performed on HIV RNA in stored plasma samples. Tests were performed to identify isolates with the 11/ 25 genotype, a characteristic that is associated with the SI phenotype. Detection of the 11/25 genotype has been proposed as a reliable method for sequence-based predictions of the viral phenotype of HIV clones [11] .
Statistical analyses were performed using distribution-free methods. Categorical variables and continuous variables were compared using Pearson's x 2 test and the Wilcoxon rank sum test, respectively. Variables that were found to be marginally significant or significant in univariate Cox proportional hazard analyses were used in multivariate models to predict the time to reinitiation of HAART after TI. The potential explanatory variables that were examined included age, sex, nadir CD4 cell count at pretreatment baseline and at the initiation of TI, plasma viral load at the initiation of TI, and 11/25 genotype. Event-free patients (those who did not reinitiate HAART) were right censored as of 28 February 2003.
Analyses were performed using SAS software (version 8.0; SAS), and all tests of significance were 2-sided. was P ! .05 considered to be statistically significant, and was .05 р P ! .10 considered to be marginally statistically significant.
RESULTS
Of the 4461 patients whose charts were reviewed, 208 (4.7%) underwent TI. V3 genotyping was successful for a total of 197 (94.7%) of these 208 patients, and this final group was used for all analyses. Table 1 shows the characteristics of the study patients overall and stratification by reinitiation of HAART. Of the 197 study patients, 181 (91.9%) were male. The median CD4 cell count at pretreatment baseline was 385 cells/mm , and the median plasma viral load was 1.69 log 10 copies/mL (IQR, 1.65-3.03 log 10 copies/mL; in 61% of subjects it was !50 copies/mL).
Fifty-nine patients (29.9%) reinitiated HAART by the end of the study (table 1) . The median duration of TI in patients who reinitiated HAART was 15 months (IQR, 6-23 months). Patients who reinitiated HAART by the end of the study had significantly lower median nadir CD4 cell counts and higher median plasma viral loads at the initiation of TI than did patients who did not reinitiate HAART by the end of the study Figure 2 . A, Medians and interquartile ranges of CD4 cell counts at and after the reinitiation of highly active antiretroviral therapy (HAART) after treatment interruption (TI), based on the last CD4 cell count measured during each period. B, Proportion of patients with plasma viral load !50 copies/ mL at and after the reinitiation of HAART after TI, based on the last plasma viral load measured during each period.
(
, for all comparisons). At the reinitiation of HAART, P ! .05 the median plasma viral load was 15.0 log 10 copies/mL (IQR, 4.73 to 15.0 log 10 copies/mL). As is shown in table 1, there was a higher proportion of patients with the 11/25 genotype among those who reinitiated HAART than among those who did not (18.6% vs. 5.8%, respectively;
). During TI, the rate P p .005 of decline in the CD4 cell count was similar in patients with and without the 11/25 genotype (median decline, 10.3 vs. 10.8 cells/mm 3 /month, respectively;
). The 6 deaths that P p .966 occurred during the study period were not considered to be directly attributable to HIV infection or TI.
In a univariate analysis of time to reinitiation of HAART (table 2), age, pretreatment baseline CD4 cell count, nadir CD4 cell count, CD4 cell count at the initiation of TI, plasma viral load at the initiation of TI, and the 11/25 genotype were found to be marginally significantly or significantly associated with time to reinitiation of HAART. The probabilities of continuing TI, stratified by nadir CD4 cell count and 11/25 genotype, are shown in figure 1A and 1B, respectively.
Although 94.0% (SE, ‫)%1.2ע‬ of patients with nadir CD4 cell counts 1250 cells/mm 3 were continuing TI at 12 months, only 61.1% (SD, ‫)%2.7ע‬ of those with nadir CD4 cell counts р250 cells/mm 3 did so. The rate of reinitiation of HAART was significantly greater in those with nadir CD4 cell counts of 200-250 cells/mm 3 ( , log-rank test) ( figure 1A ). For all eval-P ! .001 uated strata, there were no statistically significant differences in the probability of reinitiating HAART, as long as the nadir CD4 cell count was 1250 cells/mm 3 . In a multivariate analysis ( ) were associated with a faster P p .031 time to the reinitiation of HAART, after adjusting for age and plasma viral load at the initiation of TI. Models 2 and 3 (table 3) show similar associations when CD4 cell counts at pretreatment baseline and at the initiation of TI were used in the analysis. Age was a significant predictor in all 3 multivariate models. Patients had substantial increases in CD4 cell counts and decreases in plasma viral loads after the reinitiation of HAART, as is shown in figure 2A and 2B, respectively.
DISCUSSION
In this study, the impact of TI on a group of HAART-treated patients with nadir CD4 cell counts 1200 cells/mm 3 was examined. Nadir CD4 cell count, CD4 cell count at the initiation of TI, and the 11/25 genotype were independently associated with a faster time to the reinitiation of HAART in this cohort.
TI has been explored as a possible way to ameliorate the complexity of HAART regimens, drug toxicities, viral resistance, and exhaustion of treatment options [12] [13] [14] . Previous studies have suggested that pretreatment nadir CD4 cell count and plasma viral load can be used as predictors of outcome in the setting of treatment discontinuation [15] . This is consistent with the notion that interruption of HAART consistently leads to a decrease in CD4 cell count and an increase in plasma viral load to pre-antiretroviral therapy levels. As such, caution is warranted in recommending TI to patients with low CD4 cell counts, because it may put them at risk for disease progression and, after the reinitiation of HAART, their CD4 cell counts may not return to baseline levels for several months [16] .
The present study shows that a nadir CD4 cell count !250 cells/mm 3 and a high plasma viral load at the initiation of TI suggest that there will be a faster time to the reinitiation of HAART. Physicians should also take into account CD4 cell count variability, which approaches 30% [17] . If the CD4 cell count at the initiation of TI was ∼250 cells/mm 3 , this could reflect a CD4 cell count that is as low as 175 cells/mm 3 ; hence, these patients are more likely to need to reinitiate HAART sooner than patients whose CD4 cell counts are 1250 cells/mm 3 . Also of importance is that the 11/25 genotype was a determining factor in identifying patients who were likely to have a shorter time to the reinitiation of HAART. In studies published elsewhere, the SI phenotype has been associated with an accelerated decrease in CD4 cell count and accelerated disease progression [6, 18] . These results are consistent with the results of a study published during the pre-HAART era, showing that patients with the NSI HIV phenotype took 3 times as long as those with the SI HIV phenotype to have a given decrease in CD4 cell count [18] . However, our analysis showed no difference between patients with and without the 11/25 genotype in the rate of decline in CD4 cell count, although this lack of difference was possibly due to a lack of power to detect it.
An important strength of our study is its basis in a populational database; it should, therefore, be widely applicable to other HIV-infected populations. A possible limitation of our study is that it is based on a predominantly white male population sample, which reflects the epidemiological characteristics of HIV infection in our region. However, on the basis of our previous work [19] , we believe it is unlikely that the findings of the present study are sex specific. Finally, the findings of the present study are restricted to adults infected with HIV and therefore cannot be readily extrapolated to the situation in pediatric HIV infection.
In summary, the results of our study suggest that TI is a viable option for HIV-positive adults without an AIDS-defining illness and with nadir CD4 cell counts 1250 cells/mm 3 . A nadir CD4 cell count of 200-250 cells/mm 3 and the 11/25 genotype were found to be associated with a faster time to the reinitiation of HAART. This information should be valuable when considering a TI, particularly for patients who initiated HAART during the past several years in accordance with present guidelines. Additional follow-up of this and similar cohorts will be needed to fully characterize long-term outcomes associated with elective TI.
